News

May 25, 2021

AffyImmune Co-founder Dr. Moonsoo Jin Receives Highly Selective R01 Grant from NCI

May 17, 2021

AffyImmune Therapeutics’ AIC100 Granted Fast Track Designation for Treating Thyroid Cancer

October 29, 2020

AffyImmune Therapeutics Announces First Patient Enrolled in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer

June 29, 2020

AffyImmune Therapeutics presents novel CAR T development programs at the annual meeting of the American Association of Cancer Research

October 30, 2019

AffyImmune Therapeutics Announces IND Approval for a First-in-Man Trial of Affinity-Tuned CAR T cells for Patients with Advanced, Refractory Thyroid Cancer